How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

931 results for

Human Papilloma Virus Vaccine

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Immune Response Evaluation to Curative Conventional Therapy

Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by Simon Laban, MD, University of Ulm: Head and Neck Squamous Cell Carcinoma cancer-specific immunity cancer immunology cancer-testis antigens human papilloma virus immune modulatory cells Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms (...) this trial will help to understand how state of the art treatment can be complemented using cancer-testis antigen specific vaccines and immune-modulating drugs to improve the outcome of head and neck cancer patients. Condition or disease Head and Neck Squamous Cell Carcinoma Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 22 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Immune Response Evaluation to Curative

2017 Clinical Trials

162. Characterization of the tumor T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Full Text available with Trip Pro

and the mRNA expression levels of immune-related genes with clinicopathologic parameters.Results: Clonal expansion of T cells was significantly higher in human papilloma virus (HPV)-negative compared with HPV-positive tumors, signifying more robust antigen presentation in HPV-negative tumors. The latter was supported by the higher percentage of HPV-negative tumors expressing HLA-A protein compared with HPV-positive tumors (P = 0.049). Higher GRZB levels correlated significantly with longer recurrence-free (...) Characterization of the tumor T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Purpose: Squamous cell carcinoma of the head and neck (SCCHN) is a lethal cancer with a suboptimal 5-year overall survival of approximately 50% with surgery and/or definitive chemoradiotherapy. Novel treatments are thus urgently awaited. Immunotherapy with checkpoint blockade has emerged as a promising option for patients

2017 Clinical Cancer Research

163. Absence of γ-chain in keratinocytes alters chemokine secretion resulting in reduced immune cell recruitment. Full Text available with Trip Pro

-deficient keratinocytes also exhibit defective induction of T-cell chemotaxis in a model of stable human papilloma virus-18 infection. These findings suggest that persistent γc-deficiency in keratinocytes alters immune cell recruitment to the skin, which may contribute to the development and persistence of warts in this condition and would require different treatment approaches.Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. (...) human papilloma virus infections persists, possibly related to persistent γc-deficiency in other cell types. Here we show that keratinocytes, the only cell type directly infected by human papilloma virus, express functional γc and its co-receptors. After stimulation with the γc-ligand IL-15, γc-deficient keratinocytes show significantly impaired secretion of specific chemokines including CXCL1, CXCL8, and CCL20, resulting in reduced chemotaxis of dendritic cells and CD4+ T cells. Furthermore, γc

2017 Journal of Investigative Dermatology

164. Harnessing Nanoparticles for Immunomodulation and Vaccines Full Text available with Trip Pro

Harnessing Nanoparticles for Immunomodulation and Vaccines The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. The great interest in NPs is likely not only a result of the two successful vaccines against hepatitis B and Human Papilloma Virus (HPV (...) ) that use this technology, but also due to the versatility of those small-sized particles, as indicated by the wide range of applications reported so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems.

2017 Vaccines

165. On the implications of desexualizing vaccines against sexually transmitted diseases: health policy challenges in a multicultural society Full Text available with Trip Pro

On the implications of desexualizing vaccines against sexually transmitted diseases: health policy challenges in a multicultural society Two vaccines against sexually transmitted infections are included in many national vaccination programs: Hepatitis B Virus (HBV) vaccine and Human Papilloma Virus (HPV) vaccine. The trajectories of the implementation of these two programs were marked by differences in the way the sexual context of risk was communicated to the public. These trajectories (...) fluctuated between full accounts of the sexual nature of the infection and attempts to desexualize the vaccines. Vaccine desexualization can be achieved by withholding information of sexual context, blurring information, and distancing the age of vaccination from the age of sexual debut. Desexualization may be advantageous in promoting public health and personal health of people who believe that HPV vaccination leads to increased promiscuity, people who believe that protection against STD is not relevant

2017 Israel journal of health policy research

166. Passed the Age of Puberty: Organizational Networks as a Way to Get Things Done in the Health Field: Comment on "Evaluating Global Health Partnerships: A Case Study of a Gavi HPV Vaccine Application Process in Uganda" Full Text available with Trip Pro

Passed the Age of Puberty: Organizational Networks as a Way to Get Things Done in the Health Field: Comment on "Evaluating Global Health Partnerships: A Case Study of a Gavi HPV Vaccine Application Process in Uganda" In this commentary I will demonstrate that the case study of Uganda's Human papilloma virus (HPV) vaccine application partnership provides an excellent example of widening our lens by evaluating the successful HPV vaccine coverage from a network-centric perspective. That implies

2017 International journal of health policy and management

167. Louisiana Physicians Are Increasing HPV Vaccination Rates Full Text available with Trip Pro

Louisiana Physicians Are Increasing HPV Vaccination Rates Human papilloma virus (HPV) is a common virus that can cause genital warts and certain cancers. The HPV vaccine is effective in preventing many HPV-associated diseases, however, vaccination rates suggest many remain unprotected. This study examined successful strategies used by physicians to improve HPV vaccination rates. Providers with above average vaccination rates were identified. A representative from each provider participated (...) in an interview to identify strategies used to boost HPV vaccination. Key strategies in ensuring vaccine completion were reminders, education, standing orders, and scheduling future vaccine appointments at time of first dose. Other successful strategies included coupling the HPV vaccine with adolescent vaccines, administering during well-visits, and recommending the vaccine as protection against cancer and genital warts. Findings suggest successful and widely used methods among high performing providers

2017 The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society

168. Knowledge and Awareness about Cervical Cancer Vaccine (HPV) Among Parents in Sharjah Full Text available with Trip Pro

Knowledge and Awareness about Cervical Cancer Vaccine (HPV) Among Parents in Sharjah Background and aim: Cervical cancer (CC) is the 7th most common cancer worldwide. It is the 4th most common cancer in females causing 7.5% of all female cancer deaths. Human Papilloma Virus (HPV) infection is the leading cause of CC and other diseases worldwide. Despite several measures taken to reduce the risk of infection with HPV, the most effective method remains the HPV vaccine. The aim of this study (...) was to assess the knowledge and attitudes of parents in Sharjah towards HPV and whether or not they would vaccinate their daughters. Methods and Material: A quantitative, observational cross-sectional study of 400 subjects was conducted in public venues in Sharjah. Probability sampling method was used for selection of subjects (parents who have daughters). A self-administered 32- question questionnaire was distributed. SPSS 21 (Statistical Package for Social Sciences) was used for entry and analysis of data

2017 Asian Pacific journal of cancer prevention : APJCP

169. HPV Vaccination in Women With Cystic Fibrosis

Questionnaire Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 74 participants Observational Model: Other Time Perspective: Prospective Official Title: HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region Actual Study Start Date : September 25, 2017 Actual Primary Completion Date : December 15, 2017 Actual Study Completion Date : December 15, 2017 Resource links provided by the National (...) papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population. The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination. Condition or disease Intervention/treatment Human Papillomavirus Infection Other: Self-report Written

2017 Clinical Trials

170. Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response

Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention Official Title: Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Actual Study Start Date : November 15, 2017 Estimated Primary Completion Date : March 2020 Estimated Study Completion Date : April 2020 Resource links provided by the National (...) virus (HCV) or Hepatitis B virus (HBV) (Ag HBS) tests; Patients whose regular partner(s) have active uncontrolled clinical EGW; Patients who received the HPV Vaccine at any time before enrolment to the study; Any serious chronic or progressive disease according to the judgement of the investigator; Patients with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids

2017 Clinical Trials

171. Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients

years, most patients seek treatment because the warts are unsightly and often tender or painful. Condition or disease Intervention/treatment Phase Genital Wart Biological: tuberculin Device: cryotherapy Phase 3 Detailed Description: Genital warts are highly contagious sexually transmitted diseases (STD) caused by infection of Human Papilloma Virus and, as the most common STD in developed countries, can currently be considered to be globally epidemic. It is estimated that the frequency of Human (...) : May 17, 2017 See Sponsor: Assiut University Information provided by (Responsible Party): Mena Ramsis Haleem, Assiut University Study Details Study Description Go to Brief Summary: Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several

2017 Clinical Trials

172. Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts

such as mumps, Candida, and tuberculin has been proved effective in the treatment of warts. The exact mechanism of action of intralesional immunotherapy is still obscure. Intralesional antigen injection probably induces strong non specific inflammatory response against the human papilloma virus-infected cells. It has been suggested that intralesional measles mumps rubella vaccine results in regression of warts via induction of immune system. Study Design Go to Layout table for study information Study Type (...) . ClinicalTrials.gov Identifier: NCT03183765 Recruitment Status : Recruiting First Posted : June 12, 2017 Last Update Posted : February 23, 2018 See Sponsor: Assiut University Information provided by (Responsible Party): GAbdelsamea, Assiut University Study Details Study Description Go to Brief Summary: Warts are benign epidermal tumors caused by human papilloma virus, which are epitheliotropic non-enveloped double stranded DNA viruses. Transmission of warts occurs from direct person-to-person contact

2017 Clinical Trials

173. Therapeutic use of the HPV vaccine in Recurrent Respiratory Papillomatosis: A case report. (Abstract)

Therapeutic use of the HPV vaccine in Recurrent Respiratory Papillomatosis: A case report. Recurrent Respiratory Papillomatosis (RRP) is a condition characterized by recurring squamous papillomas in the aerodigestive tract due to Human Papilloma Virus (HPV) infection. Treatment includes surgical debridement of the lesions often with adjuvant therapy. A newer adjuvant agent being tested is the HPV vaccine. The case report includes a child with RRP who underwent 10 surgeries in a year (...) with an average inter-surgical interval (ISI) of 46 days. The patient then received the scheduled regimen of 3 doses of 9 valent HPV vaccine. Since beginning the vaccination, her average ISI increased to 113 days and as of writing of this paper only 1 surgery in the last 340 days. It is theorized that the increase in humoral response to the virus can slow the course of the disease, lengthen the ISI, and decrease morbidity. The results of this case report lends evidence to the use of the HPV vaccine

2017 International Journal of Pediatric Otorhinolaryngology

174. Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination

using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection. The research is focused on these questions: Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members (...) /treatment Papillomavirus Infections Health Behavior Attitude of Health Personnel Human Papilloma Virus, Male Other: Survey Detailed Description: This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9

2016 Clinical Trials

175. A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

and Prevention Information provided by (Responsible Party): Shanghai Zerun Biotechnology Co.,Ltd Study Details Study Description Go to Brief Summary: A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Healthy Females Aged 18-30 Years. Condition or disease Intervention/treatment Phase Human Papilloma (...) Virus Infection Type 16 Human Papilloma Virus Infection Type 18 Cervical Intraepithelial Neoplasia Biological: HPV-16/18 vaccine Biological: HPV-16/18 placebo Phase 3 Detailed Description: This is a multi-centre, randomized, double blinded, placebo controlled study. The study vaccine is recombinant human papillomavirus bivalent (types 16 and 18) vaccine (Yeast), the placebo is aluminium phosphate diluent. This study planned to enrol 12000 healthy female aged 18-30 in 10 study sites. Each

2016 Clinical Trials

176. The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach. Full Text available with Trip Pro

The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach. Cervical cancer, a preventable disease, is the third leading cause of cancer morbidity and mortality in the Lao People's Democratic Republic (Lao PDR). Since many cervical cancers are linked to human papilloma virus (HPV) infection, vaccination against this virus may lead to a reduction in these types of cancer. The study described here (...) is the first to compare the cost-effectiveness of different HPV vaccination options in Lao PDR.A dynamic compartment model was created. The model included routine screening activities already in place, as well as theoretical interventions that included a 10-year old girl-only vaccination programme combined with/without a 10-year old boy vaccination programme and/or a catch-up component. The simulation was run over 100 years. In base case analyses, we assumed 70 % vaccination coverage with lifelong

2016 BMC health services research

177. The Association of High Risk Human Papillomaviruses in Patients With Cervical Cancer: An Evidence Based Study on Patients With Squamous Cell Dysplasia or Carcinoma for Evaluation of 23 Human Papilloma Virus Genotypes Full Text available with Trip Pro

The Association of High Risk Human Papillomaviruses in Patients With Cervical Cancer: An Evidence Based Study on Patients With Squamous Cell Dysplasia or Carcinoma for Evaluation of 23 Human Papilloma Virus Genotypes Cervical cancer is one of the leading causes of cancer-related death in females. Human papilloma virus (HPV) is the major risk factor of cervical cancer.The aim of the current study was to explore the frequency and role of 23 different HPVs in patients with cervical cancer.Overall (...) transmitted disease with relative frequency of 0.58. Infection with papilloma virus was observed in 83.6% of SCC patients and 45% of the dysplasia group. The most prevalent HPV genotypes were 18 with 31.62% and 16 with 27.35% of cases. Moreover the relative frequencies of HPV-33, -6, -58, -52, -35 and -51, genotypes were 15.38, 7.69, 5.98, 5.12 and 3.41%, respectively. Among the different genotypes of HPV, 31 had the lowest and 16 had the highest relative frequency.Our findings demonstrate that HPV-16

2016 Jundishapur journal of microbiology

178. A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

: Other Study ID Numbers: HPV-PRO-006 First Posted: September 29, 2015 Last Update Posted: August 16, 2018 Last Verified: August 2018 Keywords provided by Jun Zhang, Xiamen University: Human Papilloma Virus 16 Human Papilloma Virus 18 vaccine adolescent girl bridging trial non-inferiority Additional relevant MeSH terms: Layout table for MeSH terms Uterine Cervical Neoplasms Neoplasms Carcinoma in Situ Cervical Intraepithelial Neoplasia Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms (...) systemic lupus erythematosus), rheumatoid arthritis, asplenia or splenectomy due to any conditions, and other immunological diseases that may impact immune response as considered by investigator), etc.; Participants with a history of allergy, including severe adverse reactions due to the past vaccination, such as hypersensitivity, urticaria, dyspnea, angioneurotic edema, or abdominal pain; Participants with asthma, which is unstable in the past 2 years, requiring emergency treatment, hospitalization

2015 Clinical Trials

179. Rare subtype(s) and frequency of multi-viral subtype high-risk human papilloma virus infection in high-grade squamous intraepithelial lesion and squamous cell carcinoma in a cervical carcinoma prevalent developing country: a multiplex real-time polymerase Full Text available with Trip Pro

Rare subtype(s) and frequency of multi-viral subtype high-risk human papilloma virus infection in high-grade squamous intraepithelial lesion and squamous cell carcinoma in a cervical carcinoma prevalent developing country: a multiplex real-time polymerase Bangladesh, with a population of 160 million and nearly half being women, has the 4th highest rate of cervical carcinoma deaths in the world. It is projected that ∼500,000 of these women would die of this entirely preventable cancer by 2030 (...) . This finding is in sharp contrast to the reports from western countries of frequent multi-viral and rare subtype hrHPV infection. This pilot study suggests that a vaccination program may be highly effective in controlling cervical cancer there. A larger study, however, is required to ratify the findings.

2016 Diagnostic pathology

180. Prevalence of Human Papilloma Virus Infection in Young Primiparous Women During Postpartum Period: Study from a Tertiary Care Center in Northern India Full Text available with Trip Pro

Prevalence of Human Papilloma Virus Infection in Young Primiparous Women During Postpartum Period: Study from a Tertiary Care Center in Northern India Assessment of high-risk Human Papilloma Virus (HPV) prevalence is important for monitoring long-term decrease in cervical cancer after implementation of the prophylactic HPV vaccination.To determine the prevalence of high-risk HPV infection and cytological abnormalities in young primiparous women in the age group of 16-26years.In this cross (...) (4.2%), HPV 45 in six (2.8%) and HPV 31 in four (1.8%) women. Five women tested positive for more than one HPV types. There were no cases of intraepithelial lesions or cervical cancer. One patient who had Atypical Cells of Undetermined Significance (ASCUS) on cytology tested negative for all four HPV genotypes.This study provides a geographic baseline data of high-risk HPV prevalence in young Indian women before implementation of a vaccination program. The results are important for comparison

2016 Journal of clinical and diagnostic research : JCDR

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>